Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Kazuto ItoMikio KobayashiMotokiyo KomiyamaSeiji NaitoKazuo NishimuraJunji YoneseKatsuyoshi HashineShiro SaitoGaku AraiMitsuru ShinoharaNaoya MasumoriNobuaki ShimizuTakefumi SatohAtsushi YamauchiTatsuo TochigiYutaka TakezawaHiroyuki FujimotoAkira YokomizoKen-Ichi KakimotoIwao FukuiKatsuyuki KarasawaTaiji TsukamotoMiwako NozakiMasaru HasumiHiromichi IshiyamaMikinobu OhtaniMasaaki KuwaharaMasaoki HaradaYasuo OhashiToshihiko KotakeTadao KakizoeKazuhiro SuzukiHidetoshi Yamanakanull nullPublished in: Cancer (2020)
Although modified bRFS data did not demonstrate noninferiority for arm 2, intermittent adjuvant ADT after EBRT with 14 months of neoadjuvant and short-term adjuvant ADT is a promising treatment strategy, especially in a population of responders after 6 months of ADT for locally advanced PCa.
Keyphrases
- locally advanced
- rectal cancer
- radiation therapy
- prostate cancer
- early stage
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radical prostatectomy
- high intensity
- double blind
- lymph node
- open label
- type diabetes
- big data
- placebo controlled
- robot assisted
- phase ii
- artificial intelligence
- insulin resistance
- study protocol
- combination therapy
- smoking cessation